OBJECTIVE: C-reactive protein (CRP) is an inflammatory marker that contributes to the prediction of cardiovascular disease. We investigated the influences of CRP polymorphisms on baseline CRP levels and fenofibrate-induced CRP changes in subjects with the metabolic syndrome. RESEARCH DESIGN AND METHODS: We examined the association of CRP single nucleotide polymorphisms (SNPs) (m772A>G, m301G>A >T, i178T>A, 3u1273C>T, and 3u2131C>T) with baseline plasma CRP levels among 1,123 white U.S. participants in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study and the modulating effect of these SNPs on CRP response to a 3-week fenofibrate treatment among 290 participants with the metabolic syndrome. RESULTS: There were strong associations of m301G>A>T (rs3091244; P = 0.003), i178T>A (rs1417938; P = 0.001), 3u1273C>T (rs1130864; P = 0.001), and 3u2131C>T (rs1205; P < 0.001) with baseline CRP levels. Moreover, among subjects with the metabolic syndrome, fenofibrate induced the greatest reduction in CRP levels for TT subjects of the i178T>A compared with TA and AA subjects (-30 for TT, -19 for TA, and -11% for AA; P = 0.004). Similarly, for the m301G>A>T, major allele carriers displayed maximal reduction of CRP over noncarriers (-20 for GG, -15 for GA and GT, and -0.3% for TA and AA; P = 0.020). CONCLUSIONS: Our results demonstrate that common genetic variants within the CRP gene affect baseline CRP levels and further modulate CRP response in subjects with the metabolic syndrome treated with fenofibrate. This knowledge could contribute to a better prediction of therapeutic success.
OBJECTIVE:C-reactive protein (CRP) is an inflammatory marker that contributes to the prediction of cardiovascular disease. We investigated the influences of CRP polymorphisms on baseline CRP levels and fenofibrate-induced CRP changes in subjects with the metabolic syndrome. RESEARCH DESIGN AND METHODS: We examined the association of CRP single nucleotide polymorphisms (SNPs) (m772A>G, m301G>A >T, i178T>A, 3u1273C>T, and 3u2131C>T) with baseline plasma CRP levels among 1,123 white U.S. participants in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study and the modulating effect of these SNPs on CRP response to a 3-week fenofibrate treatment among 290 participants with the metabolic syndrome. RESULTS: There were strong associations of m301G>A>T (rs3091244; P = 0.003), i178T>A (rs1417938; P = 0.001), 3u1273C>T (rs1130864; P = 0.001), and 3u2131C>T (rs1205; P < 0.001) with baseline CRP levels. Moreover, among subjects with the metabolic syndrome, fenofibrate induced the greatest reduction in CRP levels for TT subjects of the i178T>A compared with TA and AA subjects (-30 for TT, -19 for TA, and -11% for AA; P = 0.004). Similarly, for the m301G>A>T, major allele carriers displayed maximal reduction of CRP over noncarriers (-20 for GG, -15 for GA and GT, and -0.3% for TA and AA; P = 0.020). CONCLUSIONS: Our results demonstrate that common genetic variants within the CRP gene affect baseline CRP levels and further modulate CRP response in subjects with the metabolic syndrome treated with fenofibrate. This knowledge could contribute to a better prediction of therapeutic success.
Authors: Francesco D'Aiuto; Juan P Casas; Tina Shah; Steve E Humphries; Aroon D Hingorani; Maurizio S Tonetti Journal: Atherosclerosis Date: 2004-12-18 Impact factor: 5.162
Authors: D T Miller; R Y L Zee; J Suk Danik; P Kozlowski; D I Chasman; R Lazarus; N R Cook; P M Ridker; D J Kwiatkowski Journal: Ann Hum Genet Date: 2005-11 Impact factor: 1.670
Authors: D J Brull; Norma Serrano; F Zito; Lisa Jones; H E Montgomery; A Rumley; Pankaj Sharma; G D O Lowe; M J World; S E Humphries; A D Hingorani Journal: Arterioscler Thromb Vasc Biol Date: 2003-07-03 Impact factor: 8.311
Authors: Robert S Rosenson; David A Wolff; Anna L Huskin; Irene B Helenowski; Alfred W Rademaker Journal: Diabetes Care Date: 2007-05-04 Impact factor: 19.112
Authors: Dolores Corella; Donna K Arnett; Michael Y Tsai; Edmond K Kabagambe; James M Peacock; James E Hixson; Robert J Straka; Michael Province; Chao-Qiang Lai; Laurence D Parnell; Ingrid Borecki; Jose M Ordovas Journal: Clin Chem Date: 2007-04-19 Impact factor: 8.327
Authors: Robert Kleemann; Philippe P Gervois; Lars Verschuren; Bart Staels; Hans M G Princen; Teake Kooistra Journal: Blood Date: 2002-08-29 Impact factor: 22.113
Authors: Ana Luisa Miranda-Vilela; Graciana Souza Lordelo; Arthur Kenji Akimoto; Penha Cristina Zaidan Alves; Luiz Carlos da Silva Pereira; Maria de Nazaré Klautau-Guimarães; Cesar Koppe Grisolia Journal: Genes Nutr Date: 2011-04-11 Impact factor: 5.523
Authors: Aldi T Kraja; Michael A Province; Robert J Straka; Jose M Ordovas; Ingrid B Borecki; Donna K Arnett Journal: Endocr Metab Immune Disord Drug Targets Date: 2010-06 Impact factor: 2.895
Authors: Stella Aslibekyan; Edmond K Kabagambe; Marguerite R Irvin; Robert J Straka; Ingrid B Borecki; Hemant K Tiwari; Michael Y Tsai; Paul N Hopkins; Jian Shen; Chao-Qiang Lai; Jose M Ordovas; Donna K Arnett Journal: Pharmacogenet Genomics Date: 2012-03 Impact factor: 2.089